Bookbuilding IPO | ₹70 Cr | Listed at BSE SME | Tue, Nov 11, 2025 - Thu, Nov 13, 2025
Mahamaya Lifesciences IPO is a book build issue of ₹70.44 crores. The issue is a combination of fresh issue of 0.56 crore shares aggregating to ₹64.28 crores and offer for sale of 0.05 crore shares aggregating to ₹6.16 crores.
Mahamaya Lifesciences IPO bidding started from Nov 11, 2025 and ended on Nov 13, 2025. The allotment for Mahamaya Lifesciences IPO was finalized on Nov 14, 2025. The shares got listed on BSE SME on Nov 18, 2025.
Mahamaya Lifesciences IPO price band is set at ₹114 per share. The lot size for an application is 1,200. The minimum amount of investment required by an individual investor (retail) is ₹2,73,600 (2,400 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,600 shares), amounting to ₹4,10,400.
Oneview Corporate Advisors Pvt.Ltd. is the book running lead manager and Kfin Technologies Ltd. is the registrar of the issue. The Market Maker of the company is Mansi Share & Stock Broking Pvt.Ltd..
Refer to Mahamaya Lifesciences IPO RHP for detailed Information.
IPO Open
Tue, Nov 11, 2025
IPO Close
Thu, Nov 13, 2025
Issue Price
₹114 per share
Market Cap (Pre-IPO)
₹266.82 Cr
| IPO Date | 11 to 13 Nov, 2025 |
| Listed on | Tue, Nov 18, 2025 |
| Face Value | ₹10 per share |
| Price Band | ₹108 to ₹114 |
| Issue Price | ₹114 per share |
| Lot Size | 1,200 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 61,78,800 shares (agg. up to ₹70 Cr) |
| Reserved for Market Maker | 3,09,600 shares Mansi Share & Stock Broking Pvt.Ltd. (agg. up to ₹4 Cr) |
| Fresh Issue (Ex Market Maker) | 53,29,200 shares (agg. up to ₹61 Cr) |
| Offer for Sale | 5,40,000 shares of ₹10 (agg. up to ₹6 Cr) |
| Net Offered to Public | 58,69,200 shares (agg. up to ₹67 Cr) |
| Share Holding Pre Issue | 1,77,66,200 shares |
| Share Holding Post Issue | 2,34,05,000 shares |
| BSE Script Code | 544611 |
| ISIN | INE0U9D01019 |
Mahamaya Lifesciences IPO comprises a total issue size of 61,78,800 shares. The net offer to the public is 58,69,200 shares, after excluding 3,09,600 shares allotted on a firm basis. Of the Net offer 29,28,000 (49.89%) are allocated to QIB, 8,82,000 (15.03%) allocated to NII 20,59,200 (35.08%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 29,28,000 | 49.89% | 47.39% |
| − Anchor Investor Shares Offered | 17,52,000 | 28.36% | |
| − QIB (Ex. Anchor) Shares Offered | 11,76,000 | 19.03% | |
| NII (HNI) Shares Offered | 8,82,000 | 15.03% | 14.27% |
| − bNII > ₹10L | 5,88,000 | 9.52% | |
| − sNII < ₹10L | 2,94,000 | 4.76% | |
| Retail Shares Offered | 20,59,200 | 35.08% | 33.33% |
| Firm Reservations | |||
| Market Maker Shares Offered | 3,09,600 | 5.01% | |
| Total Shares Offered | 61,78,800 | 100.00% | 100.00% |
Investors can bid for a minimum of 2,400 shares and in multiples of 1,200 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,400 | ₹2,73,600 |
| Individual investors (Retail) (Max) | 2 | 2,400 | ₹2,73,600 |
| S-HNI (Min) | 3 | 3,600 | ₹4,10,400 |
| S-HNI (Max) | 7 | 8,400 | ₹9,57,600 |
| B-HNI (Min) | 8 | 9,600 | ₹10,94,400 |
Mahamaya Lifesciences IPO raises ₹19.97 crore from anchor investors. Mahamaya Lifesciences IPO Anchor bid date is November 10, 2025.
📝 Anchor Investors Letter (PDF)
| Bid Date | Mon, Nov 10, 2025 |
| Shares Offered | 17,52,000 |
| Anchor Portion (₹ Cr.) | 19.97 |
| Anchor lock-in period end date for 50% shares (30 Days) | Sat, Dec 13, 2025 |
| Anchor lock-in period end date for remaining shares (90 Days) | Wed, Feb 11, 2026 |
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management and to help the farming community for more productivity.
The company specializes in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs).
The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).
The company has invested in global product registrations, with active markets in countries like the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations.
Product Portfolio:
Competitive Strengths:
Mahamaya Lifesciences Ltd.'s revenue increased by 64% and profit after tax (PAT) rose by 148% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 218.87 | 188.35 | 112.07 | 77.88 |
| Total Income | 84.04 | 267.17 | 162.83 | 137.40 |
| Profit After Tax | 4.10 | 12.94 | 5.22 | 3.75 |
| EBITDA | 8.04 | 24.64 | 13.36 | 8.91 |
| NET Worth | 53.50 | 49.42 | 24.66 | 19.44 |
| Reserves and Surplus | 35.73 | 31.66 | 23.41 | 18.19 |
| Total Borrowing | 57.72 | 58.11 | 54.63 | 24.37 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of Equipment for existing Formulation plant | 3.75 |
| 2 | Funding capital expenditure towards setting up of a new technical manufacturing plant | 29.42 |
| 3 | Construction of Warehouse Building and Purchase of Machinery | 2.53 |
| 4 | Funding working capital requirement of our Company | 18.00 |
| 5 | General Corporate purposes | 8.26 |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 34.94% |
| ROCE | 23.15% |
| Debt/Equity | 1.08 |
| RoNW | 26.19% |
| PAT Margin | 4.84% |
| EBITDA Margin | 9.22% |
| Price to Book Value | 9.40 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 7.29 | 7.01 |
| P/E (x) | 15.65 | 16.25 |
| Promoter Holding | 77.27% | 56.35% |
| Market Cap | ₹266.82 Cr. |
The Mahamaya Lifesciences IPO is subscribed 1.63 times on November 13, 2025 6:19:33 PM (Day 3). The public issue subscribed 1.02 times in the individual investors category, 1.19 times in the QIB category, and 3.63 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Application |
|---|---|---|---|---|
| QIB (Ex Anchor) | 1.19 | 11,76,000 | 14,01,600 | 0 |
| NII* | 3.63 | 8,82,000 | 32,05,200 | 0 |
| bNII (bids above ₹10L) | 5.00 | 5,88,000 | 29,41,200 | |
| sNII (bids below ₹10L) | 0.90 | 2,94,000 | 2,64,000 | |
| Individual Investor | 1.02 | 20,59,200 | 21,07,200 | 0 |
| Total | 1.63 | 41,17,200 | 67,14,000 | 1,037 |
Total Application : 1,037
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manager fees including underwriting fees | 2.26 |
| 2 | Brokerage, selling commission | 0.05 |
| 3 | Fees payable to Registrar to the Offer | 0.01 |
| 4 | Fees to the legal counsel | 0.05 |
| 5 | Statutory Advertising expenses | 0.04 |
| 6 | Fees payable to regulators including stock exchange | 0.11 |
| 7 | Printing and stationary expenses | 0.01 |
| 8 | Miscellaneous Expenses | 0.01 |
| Price Details | BSE SME |
|---|---|
| Final Issue Price | ₹114.00 |
| Open | ₹115.00 |
| Low | ₹111.00 |
| High | ₹117.00 |
| Last Trade | ₹116.00 |
Lead Manager Reports
Mahamaya Lifesciences IPO is a SME IPO of 61,78,800 equity shares of the face value of ₹10 aggregating up to ₹70 Crores. The issue is priced at ₹114 per share. The minimum order quantity is 1200.
The IPO opens on Tue, Nov 11, 2025, and closes on Thu, Nov 13, 2025.
Kfin Technologies Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Mahamaya Lifesciences IPO using UPI as a payment gateway. Zerodha customers can apply in Mahamaya Lifesciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Mahamaya Lifesciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Mahamaya Lifesciences IPO opens on Tue, Nov 11, 2025 and closes on Thu, Nov 13, 2025.
Mahamaya Lifesciences IPO lot size is 1200, and the minimum amount required for application is ₹2,73,600, with 2 lots being the minimum application size.
You can apply in Mahamaya Lifesciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Mahamaya Lifesciences IPO will be done on Friday, November 14, 2025, and the allotted shares will be credited to your demat account by Mon, Nov 17, 2025. Check the Mahamaya Lifesciences IPO allotment status.
The Mahamaya Lifesciences IPO listing date is on Tue, Nov 18, 2025.
